Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
Coveris’ security labels also work seamlessly with self-checkouts where around 80% of retail sales now typically occur
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
Two main objectives are: Accelerate novel technologies and products for global markets; and Connect academia and industry, creating synergy for faster advancement of the Bioprotection sector
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
Subscribe To Our Newsletter & Stay Updated
